Rahal A, Péloquin L, Ahmarani C
Department of Otolaryngology-Head and Neck Surgery, Maisonneuve-Rosemont Hospital, University of Montreal, Quebec.
J Otolaryngol. 2001 Feb;30(1):1-5. doi: 10.2310/7070.2001.20838.
Mitomycin C (MMC) is an antineoplastic agent with an antiproliferative effect on fibroblasts. It is routinely used topically in ophthalmology. The goal of this research project is to evaluate if topically applied MMC at the site of a maxillary antrostomy will inhibit the healing process of the mucosa and reduce the risk of postoperative stenosis. Antrostomies were carried out in both maxillary sinuses of 10 rabbits. For each rabbit, MMC is applied at the site of the antrostomy on one side while the other side serves as control. Antrostomies are re-evaluated 3 weeks later and their areas measured precisely. Seven of 10 control antrostomies were closed compared to only 1 of the 10 treated with MMC (p = .014). Comparison of the areas of the control and treated sides also proved to be statistically significant (p = .0039). Topical application of MMC was not associated with any systemic side effects and did not cause any permanent microscopic changes since the mucosa re-epithelialized normally. These results suggest that MMC slows the postoperative healing process of the nasal mucosa of the rabbit without affecting re-epithelialization. This could allow antrostomies to heal with a wider diameter, decreasing the risk of postoperative stenosis. Our next step will be to reproduce these results following functional endoscopic surgery on humans.
丝裂霉素C（MMC）是一种对成纤维细胞具有抗增殖作用的抗肿瘤药物。它在眼科中常规用于局部用药。本研究项目的目的是评估在上颌窦造口部位局部应用MMC是否会抑制黏膜的愈合过程并降低术后狭窄的风险。对10只兔子的双侧上颌窦进行造口术。对于每只兔子，在一侧的造口部位应用MMC，而另一侧作为对照。3周后对造口进行重新评估并精确测量其面积。10个对照造口中有7个闭合，而10个用MMC治疗的造口中只有1个闭合（p = 0.014）。对照侧和治疗侧面积的比较也具有统计学意义（p = 0.0039）。局部应用MMC未出现任何全身副作用，且由于黏膜正常重新上皮化，未引起任何永久性微观变化。这些结果表明，MMC可减缓兔子鼻黏膜的术后愈合过程，而不影响重新上皮化。这可以使造口以更大的直径愈合，降低术后狭窄的风险。我们的下一步将是在人类功能性内镜手术后重现这些结果。
